Ascrinvacumab

Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) [1].

Product Specifications

CAS Number

[1463459-96-2]

Product Name Alternative

Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab) ; PF-03446962; GT-90001C

UNSPSC

12352203

Target

Anaplastic lymphoma kinase (ALK)

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ascrinvacumab.html

Purity

97.45

Solubility

10 mM in DMSO

Smiles

[Ascrinvacumab]

Molecular Weight

(144.08 kDa)

References & Citations

[1]van Meeteren LA, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9) -induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem. 2012 May 25;287 (22) :18551-61.